Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 2/20 | 0.61 |
| ▸ | CXCR4 | P61073 | 5/20 | 0.61 |
| ▸ | MC4R | P32245 | 2/20 | 0.61 |
| ▸ | MC5R | P33032 | 2/20 | 0.61 |
| ▸ | MC3R | P41968 | 2/20 | 0.61 |
| ▸ | MC1R | Q01726 | 2/20 | 0.61 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | NPY4R | P50391 | 1/20 | 0.60 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.60 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.59 |
| ▸ | GLP1R | P43220 | 4/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.58 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410247 | 0.87 | NPY1R (0.72) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29382733 | 0.87 | C5AR1 (0.63) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL30658215 | 0.87 | NPY1R (0.72) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31182780 | 0.86 | C5AR1 (0.66) | CXCR4MC4RMC5RMC3RMC1R | |
| SCHEMBL29993191 | 0.86 | IL23R (0.66) | CALCACXCR4NPY1RNPY2RNPY4R | |
| SCHEMBL30906424 | 0.85 | NPY2R (0.70) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30432210 | 0.85 | C5AR1 (0.66) | CALCACXCR4MC4RMC5RMC3R | |
| SCHEMBL9073974 | 0.85 | CXCR4 (0.72) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31462084 | 0.85 | C5AR1 (0.59) | CALCACXCR4MC4RMC5RMC3R | |
| SCHEMBL31683347 | 0.85 | NPY2R (0.71) | CXCR4NPY1RNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| US-20260077033-A1 | METHODS FOR TREATING OR PREVENTING RESPIRATORY DISEASES IN CATTLE USING POLYMERS AND POLYPLEXES FOR mRNA DELIVERY AND mRNA THERAPY | MISSISSIPPI STATE UNIVERSITY OFFICE OF TECHNOLOGY MANAGEMENT (US) | 2026-03-19 | — | — | US | claimed |
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | TWINPIG BIOLAB INC. (KR) | 2026-01-01 | — | — | US | claimed |
| US-20250228951-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | TWINPIG BIOLAB INC. (KR) | 2025-07-17 | — | — | US | claimed |
| EP-4512411-A2 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | Twinpig Biolab, Inc. (KR) | 2025-02-26 | — | — | EP | claimed |
| EP-4512410-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | Twinpig Biolab, Inc. (KR) | 2025-02-26 | — | — | EP | claimed |
| US-20250034218-A1 | ANTIMICROBIAL PEPTIDES | BIOMEDIT, INC. | 2025-01-30 | — | — | US | claimed |
| CN-119072327-A | Novel peptide-based immune anticancer agents | 双亥生命科学株式会社 | 2024-12-03 | — | — | CN | claimed |
| CN-118973601-A | ITGB2 mediated drug carrier | 双亥生命科学株式会社 | 2024-11-15 | — | — | CN | claimed |
| CN-118556072-A | Antibacterial peptide | 生物编辑有限责任公司 | 2024-08-27 | — | — | CN | claimed |
| WO-2023204329-A1 | NOVEL PEPTIDE-BASED CANCER IMMUNOTHERAPEUTIC AGENT | 트윈피그바이오랩(주) | 2023-10-26 | — | — | WO | claimed |
| WO-2023195805-A2 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | 트윈피그바이오랩(주) | 2023-10-12 | — | — | WO | claimed |
| WO-2023195802-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | 트윈피그바이오랩(주) | 2023-10-12 | — | — | WO | claimed |
| CN-115996942-A | Macrophage-targeting peptides, conjugates, compositions and uses thereof | 双亥生命科学株式会社 | 2023-04-21 | — | — | CN | claimed |
| WO-2023049162-A1 | ANTIMICROBIAL PEPTIDES | BIOMEDIT, LLC (US) | 2023-03-30 | — | — | WO | claimed |
| EP-4133115-A1 | GENETICALLY REPROGRAMMED MYCOPLASMA BACTERIA AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2023-02-15 | — | — | EP | claimed |
| EP-4103585-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | Twinpig Biolab, Inc. (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20220354957-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | US | claimed |
| WO-2022234346-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | WO | claimed |
| US-11484601-B2 | Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide | TWINPIGBIOLAB INC. (KR) | 2022-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034218-A1 | ANTIMICROBIAL PEPTIDES | CAPG, ZC3H18, CACYBP | CALCA 26/4885CXCR4 3370/4885MC4R 1481/4885 |
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | ITGB8, ITGB2, ITGA8 | CALCA 183/4885CXCR4 50/4885MC4R 773/4885 |
| US-20260077033-A1 | METHODS FOR TREATING OR PREVENTING RESPIRATORY DISEASES IN CATTLE USING POLYMERS AND POLYPLEXES FOR mRNA DELIVERY AND mRNA THERAPY | MED25, CARD19, HM13 | CALCA 2380/4885CXCR4 4033/4885MC4R 4001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.